(../../wp-content/themes/swissinfo-theme/assets/aktivgrotesk_w_rg-woff2-data.woff2)  (../../wp-content/themes/swissinfo-theme/assets/aktivgrotesk_w_lt-woff2-data.woff2)  (../../wp-content/themes/swissinfo-theme/assets/noto-serif-v20-latin_cyrillic-regular-woff2-data.woff2)  (../../wp-content/themes/swissinfo-theme/assets/noto-serif-v20-latin_cyrillic-700-woff2-data.woff2)  (../../../../web.cmp.usercentrics.eu/ui/loader.js)  (../../../../privacy-proxy.usercentrics.eu/latest/uc-block.bundle.js)   Ebola vaccine: ‘In an outbreak situation we’re racing against time’  - SWI swissinfo.ch              (91934531.html)              (https://www.swissinfo.ch/content/wp-content/uploads/sites/13/2026/08/000_B7NT9B6.jpg?ver=51076730&fit=1200,798)  (https://cdn.parsely.com/)  (https://web.cmp.usercentrics.eu/)  (https://privacy-proxy.usercentrics.eu/)  (https://swi.overlay.ebu-uer.be/)  (https://sibforms.com/)  (https://web.cmp.usercentrics.eu/)  (https://api.usercentrics.eu/)  (https://privacy-proxy.usercentrics.eu/)  (../../wp-includes/css/dist/block-library/style.min.css@m=1787604887g.css)  (../../_static/index.html@%253F-eJyVjUsOwjAMRC9EarqAsEGcJU1Na+F8lHFVuD0REhJbdqOnmTe0VxdLNs5GaXNVt0UyCBxaXIk1wCTWxgDNAqPYQ+vYeHa1wOAmLfHhYC9lDEny0CsH+tHayom7chdA8r24D6AAsIEWLVPQP0dVVEObyvN7eEvX0V+8P%252FnxeH4D0UdPiA==.css)  (../../_static/index.html@%253F-eJydjEkOwjAMRS9EcEGiwwJxlhC71FLqRv0JvT4dxJINyz+8R0tyYbIslinF8lIDeX57C8LOMxyissyUyjNqIA9IBgWAih3TeQ0n+lvzQ5IHGWVdFwXU+sntxRfs5%252F3GG%252FYY75emrW9dXbXXDwLdTTw=.css)  (../../../../sibforms.com/forms/end-form/build/sib-styles.css)  (RSD) (https://www.swissinfo.ch/eng/xmlrpc.php?rsd)   (91934531.html) (https://www.swissinfo.ch/ara/%d8%a7%d9%84%d8%b5%d8%ad%d8%a9-%d8%a7%d9%84%d8%b9%d8%a7%d9%84%d9%85%d9%8a%d8%a9/%d9%84%d9%82%d8%a7%d8%ad-%d8%a5%d9%8a%d8%a8%d9%88%d9%84%d8%a7-%d9%81%d9%8a-%d8%ae%d8%b6%d9%85-%d8%aa%d9%81%d8%b4%d9%8d%d9%91-%d9%88%d8%a8%d8%a7%d8%a6%d9%8a-%d9%86%d8%ad%d9%86-%d9%81%d9%8a-%d8%b3%d8%a8%d8%a7%d9%82-%d9%85%d8%b9-%d8%a7%d9%84%d8%b2%d9%85%d9%86/91945934) (91934531.html) (../../wp-content/client-mu-plugins/swissinfo-wp-customizations/resources/svg/swi-site-icon.svg@ver=1764341317) (../../wp-content/client-mu-plugins/swissinfo-wp-customizations/resources/png/swi-site-icon-32.png@ver=1764341317)  (../../wp-content/client-mu-plugins/swissinfo-wp-customizations/resources/png/swi-site-icon-192.png@ver=1764341317)  (https://www.swissinfo.ch/eng/wp-content/client-mu-plugins/swissinfo-wp-customizations/resources/png/swi-site-icon-180.png?ver=1764341317)    (https://www.swissinfo.ch/eng/) ([Keyboard shortcut + 1]) Jump to home page  (91934531.html#menu-toggle) ([Keyboard shortcut + 2]) Jump to navigation  (91934531.html#mega-menu-panel-toggle) ([Keyboard shortcut + 3]) Jump to horizontal navigation  (91934531.html#language-navigation-toggle) ([Keyboard shortcut + 4]) Go to language selection  (91934531.html#main-content) ([Keyboard shortcut + 5]) Jump to content     (https://www.swissinfo.ch/eng/) (Switzerland - News and perspectives - SWI swissinfo.ch)       The Swiss voice in the world since 1935             (https://www.swissinfo.ch/eng/) Home    (https://www.swissinfo.ch/eng/about-swi) About us    Find topics and contents  Search  (Search news, topics and more) ()       (91934531.html#) Sections    (https://www.swissinfo.ch/eng/geopolitics) Geopolitics    (https://www.swissinfo.ch/eng/democracy) Democracy    (https://www.swissinfo.ch/eng/science) Science    (https://www.swissinfo.ch/eng/swiss-identity/) Swiss Identity    (https://www.swissinfo.ch/eng/health-economy/) Economy    (https://www.swissinfo.ch/eng/topic/swiss-abroad-community/) Swiss Abroad       (https://www.swissinfo.ch/eng/latest-news/) Latest News    (https://www.swissinfo.ch/eng/swiss-film-selection/) Swiss Films    (https://www.swissinfo.ch/eng/videos/) Videos    (https://www.swissinfo.ch/eng/podcasts/) Podcasts    (https://www.swissinfo.ch/eng/debates/) Debates    (https://www.swissinfo.ch/eng/longform/) Special Reports    (https://www.swissinfo.ch/eng/opinions/) Opinions    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletters    (https://www.swissinfo.ch/eng/truth-or-tale-questions-answered-and-fact-checks-about-switzerland/) Ask Swissinfo    (91934531.html#) Guide to Switzerland    (https://www.swissinfo.ch/eng/switzerland-how-to/) Switzerland How-To    (https://www.swissinfo.ch/eng/education/) Education in Switzerland    (https://www.swissinfo.ch/eng/tourism-in-switzerland/) Tourism Trends    (https://www.swissinfo.ch/eng/housing-in-switzerland/) Housing in Switzerland         Follow us  (https://www.facebook.com/swissinfo)      (https://x.com/swissinfo_en)      (https://www.youtube.com/c/swissinfo)      (https://www.instagram.com/swissinfo.ch_en/)      (https://www.tiktok.com/@swissinfo.ch)         (JTI Certified) (https://www.swissinfo.ch/eng/swi-swissinfo-ch-certified-by-the-journalism-trust-initiative/47111480) Why you can trust Swissinfo       en       (91934531.html) English  en    (https://www.swissinfo.ch/ger/topic/globale-gesundheit/) Deutsch  de    (https://www.swissinfo.ch/fre/topic/sante-mondiale/) Français  fr    (https://www.swissinfo.ch/ita/topic/salute-globale/) Italiano  it    (https://www.swissinfo.ch/spa/topic/salud-global/) Español  es    (https://www.swissinfo.ch/por/topic/saude-global/) Português  pt    (https://www.swissinfo.ch/jpn/topic/%e3%82%b0%e3%83%ad%e3%83%bc%e3%83%90%e3%83%ab%e3%83%98%e3%83%ab%e3%82%b9/) 日本語  ja    (https://www.swissinfo.ch/ara/%d8%a7%d9%84%d8%b5%d8%ad%d8%a9-%d8%a7%d9%84%d8%b9%d8%a7%d9%84%d9%85%d9%8a%d8%a9/%d9%84%d9%82%d8%a7%d8%ad-%d8%a5%d9%8a%d8%a8%d9%88%d9%84%d8%a7-%d9%81%d9%8a-%d8%ae%d8%b6%d9%85-%d8%aa%d9%81%d8%b4%d9%8d%d9%91-%d9%88%d8%a8%d8%a7%d8%a6%d9%8a-%d9%86%d8%ad%d9%86-%d9%81%d9%8a-%d8%b3%d8%a8%d8%a7%d9%82-%d9%85%d8%b9-%d8%a7%d9%84%d8%b2%d9%85%d9%86/91945934) العربية  ar    (https://www.swissinfo.ch/chi/topic/%e5%85%a8%e7%90%83%e5%81%a5%e5%ba%b7/) 中文  zh    (https://www.swissinfo.ch/rus/topic/%d0%b3%d0%bb%d0%be%d0%b1%d0%b0%d0%bb%d1%8c%d0%bd%d0%be%d0%b5-%d0%b7%d0%b4%d0%be%d1%80%d0%be%d0%b2%d1%8c%d0%b5/) Русский  ru                  (https://www.swissinfo.ch/eng/my-profile/)    My profile  (https://www.swissinfo.ch/eng/my-bookmarks/)    Bookmarks  (https://www.swissinfo.ch/eng/topics-followed/)    Personal feed   (https://www.swissinfo.ch/~visitor-login?site_id=2&source=https%3A%2F%2Fwww.swissinfo.ch%2Feng%2F-%2F91934531) Sign in        Personal feed   Sign in to add topics to your feed.  (https://www.swissinfo.ch/~visitor-login?site_id=2&source=https%3A%2F%2Fwww.swissinfo.ch%2Feng%2F-%2F91934531) Sign in now              Bookmarks   Sign in to add articles to your saved list.  (https://www.swissinfo.ch/~visitor-login?site_id=2&source=https%3A%2F%2Fwww.swissinfo.ch%2Feng%2F-%2F91934531) Sign in now                  (91934531.html#mega-menu-panel) Geopolitics    (91934531.html#mega-menu-panel-1) Democracy    (91934531.html#mega-menu-panel-2) Science    (91934531.html#mega-menu-panel-3) Swiss Identity    (91934531.html#mega-menu-panel-4) Economy    (91934531.html#mega-menu-panel-5) Swiss Abroad        (https://www.swissinfo.ch/eng/international-geneva/) International Geneva     (https://www.swissinfo.ch/eng/topic/human-rights/) Human rights    (https://www.swissinfo.ch/eng/topic/global-health/) Global health    (https://www.swissinfo.ch/eng/topic/geneva-organisations/) Geneva organisations    (https://www.swissinfo.ch/eng/topic/global-trade/) Global trade    (https://www.swissinfo.ch/eng/topic/humanitarian-aid/) Humanitarian aid       (https://www.swissinfo.ch/eng/swiss-diplomacy/) Swiss diplomacy     (https://www.swissinfo.ch/eng/topic/neutrality/) Neutrality    (https://www.swissinfo.ch/eng/topic/international-cooperation/) International cooperation        (https://www.swissinfo.ch/eng/geopolitics) Top Stories     (Dolly Parton)   Restricted postal voting, US-Canada trade war, and thoughts of a Nobel scientist  (https://www.swissinfo.ch/eng/various/restricted-postal-voting-us-canada-trade-war-and-views-of-a-nobel-scientist/91943037) Read more: Restricted postal voting, US-Canada trade war, and thoughts of a Nobel scientist    ()   Is International Geneva still neutral ground?  (https://www.swissinfo.ch/eng/international-geneva/is-international-geneva-still-neutral-ground/91951655) Read more: Is International Geneva still neutral ground?    (Natalia Lashchevskaya, director of the Wings of Hope children’s home, surrounded by children.)   What happened to the orphans who fled Ukraine for Switzerland?  (https://www.swissinfo.ch/eng/foreign-affairs/what-happened-to-the-orphans-who-fled-ukraine-for-switzerland/91942268) Read more: What happened to the orphans who fled Ukraine for Switzerland?    (Teams from the International Federation of the Red Cross and Red Crescent Societies prepare for burial at Mbiyo cemetery the body of a fourth orphan who died from Ebola virus disease at an orphanage in Bunia, Ituri Province, June 19, 2026)   Ebola vaccine: ‘In an outbreak situation we’re racing against time’  (91934531.html) Read more: Ebola vaccine: ‘In an outbreak situation we’re racing against time’    (https://www.swissinfo.ch/eng/geopolitics) See all geopolitics stories       (https://www.swissinfo.ch/eng/podcasts/) Podcasts     (inside Geneva cover art work)   Inside Geneva  (https://www.swissinfo.ch/eng/inside-geneva-podcast/) Read more: Inside Geneva    (https://www.swissinfo.ch/eng/podcasts/) See all podcasts      (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletter     (Geopolitics newsletter with portraits of Dorian Valère Burkhalter and Giannis, Mavris)   Our newsletter on geopolitics  (https://www.swissinfo.ch/eng/inside-swi/our-newsletter-on-foreign-affairs/73364711) Read more: Our newsletter on geopolitics    (Newsletter international Geneva)   International Geneva  (https://www.swissinfo.ch/eng/international-geneva/international-geneva/79232229) Read more: International Geneva    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) See all newsletters            (https://www.swissinfo.ch/eng/topic/swiss-democracy/) Swiss democracy      (https://www.swissinfo.ch/eng/topic/information-wars/) Information wars      (https://www.swissinfo.ch/eng/topic/digital-democracy/) Digital Democracy      (https://www.swissinfo.ch/eng/topic/global-elections/) Global elections       (https://www.swissinfo.ch/eng/democracy) Top stories     (USA Primary Ballot)   US midterms: Democrats target voters on Swiss trams and buses  (https://www.swissinfo.ch/eng/global-elections/midterm-elections-us-democrats-urge-people-to-vote-on-swiss-trams/91959239) Read more: US midterms: Democrats target voters on Swiss trams and buses    (Campaign against the ‘No to a 10-million-strong Switzerland’ referendum)   How Google’s AI-generated overviews shape Swiss democracy  (https://www.swissinfo.ch/eng/digital-democracy/how-googles-ai-generated-overviews-shape-swiss-democracy/91949683) Read more: How Google’s AI-generated overviews shape Swiss democracy    (view from a balcony alcove over a full lecture hall)   When a former Swiss foreign minister turns her hand to acting  (https://www.swissinfo.ch/eng/swiss-democracy/when-a-former-swiss-foreign-minister-turns-her-hand-to-acting/91919217) Read more: When a former Swiss foreign minister turns her hand to acting    (https://www.swissinfo.ch/eng/democracy) See all democracy stories       (https://www.swissinfo.ch/eng/podcasts/) Swiss democracy          (vote)   How Swiss direct democracy works  (https://www.swissinfo.ch/eng/swiss-democracy/how-swiss-direct-democracy-works/89073820) Read more: How Swiss direct democracy works     (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletter     (Newsletter democracy)   Our democracy newsletter  (https://www.swissinfo.ch/eng/swiss-democracy/our-democracy-newsletter/79238472) Read more: Our democracy newsletter    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) See all newsletters            (https://www.swissinfo.ch/eng/topic/climate-solutions/) Climate solutions     (https://www.swissinfo.ch/eng/topic/glaciers-permafrost/) Glaciers & permafrost    (https://www.swissinfo.ch/eng/topic/emissions-reduction/) CO2 reduction    (https://www.swissinfo.ch/eng/topic/climate-adaptation/) Climate adaptation    (https://www.swissinfo.ch/eng/topic/energy-transition/) Energy transition       (https://www.swissinfo.ch/eng/research-frontiers/) Research frontiers     (https://www.swissinfo.ch/eng/topic/swiss-ai/) Swiss AI    (https://www.swissinfo.ch/eng/topic/space-research/) Space research        (https://www.swissinfo.ch/eng/science/) Top stories     (Elio Biadici in front of his house in Piano di Peccia, in the Maggia Valley, southern Switzerland on July, 3, 2024. Heavy thunderstorms triggered devastating debris flows and damage in the region in late June 2024.)   Why Alpine debris flows are becoming more intense and unpredictable  (https://www.swissinfo.ch/eng/climate-adaptation/why-alpine-debris-flows-are-becoming-more-intense-and-unpredictable/91643844) Read more: Why Alpine debris flows are becoming more intense and unpredictable    (A view of the summit of the Weisshorn mountain shrouded in clouds, with the Weisshorn East hanging glacier to the left, above the Bisgletscher, August 25, 2026, in canton Valais.)   Swiss experts downplay risk from unstable glacier  (https://www.swissinfo.ch/eng/glaciers-permafrost/experts-downplay-risk-from-unstable-swiss-glacier-weisshorn/91957013) Read more: Swiss experts downplay risk from unstable glacier    (Small groups decide which firms receive Innosuisse funds.)   Swiss innovation fund faces conflict of interest concerns  (https://www.swissinfo.ch/eng/best-of-srg-content/swiss-innovation-fund-faces-conflict-of-interest-concerns/91956264) Read more: Swiss innovation fund faces conflict of interest concerns    (https://www.swissinfo.ch/eng/science/) See all science stories       (https://www.swissinfo.ch/eng/podcasts/) Podcasts     (Swiss Connection)   The Swiss Connection Podcast: Hear Swiss science stories for the world  (https://www.swissinfo.ch/eng/society/the-swiss-connection-podcast-science/45223882) Read more: The Swiss Connection Podcast: Hear Swiss science stories for the world    (https://www.swissinfo.ch/eng/podcasts/) See all podcasts      (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletter     (Science newsletter Switzerland)   Our science newsletter  (https://www.swissinfo.ch/eng/archive-science/our-science-newsletter/79232247) Read more: Our science newsletter    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) See all newsletters            (https://www.swissinfo.ch/eng/demographics/) Demographics     (https://www.swissinfo.ch/eng/topic/assisted-suicide/) Assisted suicide       (https://www.swissinfo.ch/eng/culture/) Culture     (https://www.swissinfo.ch/eng/topic/swiss-cinema/) Swiss cinema    (https://www.swissinfo.ch/eng/topic/swiss-fine-arts/) Swiss fine arts       (https://www.swissinfo.ch/eng/future-of-work/) Future of Work     (https://www.swissinfo.ch/eng/topic/ai-work/) AI & Work       (https://www.swissinfo.ch/eng/history/) History       (https://www.swissinfo.ch/eng/swiss-identity/) Top stories     (Small groups decide which firms receive Innosuisse funds.)   Swiss innovation fund faces conflict of interest concerns  (https://www.swissinfo.ch/eng/best-of-srg-content/swiss-innovation-fund-faces-conflict-of-interest-concerns/91956264) Read more: Swiss innovation fund faces conflict of interest concerns    (View of Bern rooftops, January 2026. After record summer heat in Europe, attention is turning to winter. There are concerns about higher energy prices and the impact of the ongoing US-Iran war.)   Switzerland braces for winter as gas risks mount  (https://www.swissinfo.ch/eng/energy-transition/switzerland-braces-for-winter-as-gas-risks-mount/91955846) Read more: Switzerland braces for winter as gas risks mount    (In 2019, interns at the UN in Geneva protested low pay)   Inequality in intern pay is distorting the Swiss job market  (https://www.swissinfo.ch/eng/workplace/inequality-in-intern-pay-is-distorting-the-swiss-job-market/91951322) Read more: Inequality in intern pay is distorting the Swiss job market    (Thermoplan)   The threats to ‘Swiss Made’  (https://www.swissinfo.ch/eng/culture/the-threats-to-swiss-made/91949760) Read more: The threats to ‘Swiss Made’    (https://www.swissinfo.ch/eng/swiss-identity/) See all Swiss identity stories       (https://www.swissinfo.ch/eng/debates/) Debate     (debate logo)   To what extent do you think assisted suicide should be a legally available option to those who want to end their lives?  (https://www.swissinfo.ch/eng/demographics/to-what-extent-do-you-think-assisted-suicide-should-be-a-legally-available-option-to-those-who-want-to-end-their-lives/46943120) Read more: To what extent do you think assisted suicide should be a legally available option to those who want to end their lives?    (https://www.swissinfo.ch/eng/debates/) See all debates      (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletter     (Newsletter Swiss cultural scene)   Culture stories by SWI swissinfo.ch  (https://www.swissinfo.ch/eng/culture/culture-stories-by-swi-swissinfo-ch/79232241) Read more: Culture stories by SWI swissinfo.ch    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) See all newsletters            (https://www.swissinfo.ch/eng/medicine-access/) Medicine access     (https://www.swissinfo.ch/eng/topic/drug-pricing/) Drug pricing    (https://www.swissinfo.ch/eng/topic/patient-safety/) Patient safety    (https://www.swissinfo.ch/eng/topic/pharma-supply-chains/) Pharma supply chains    (https://www.swissinfo.ch/eng/topic/health-systems/) Health systems       (https://www.swissinfo.ch/eng/healthcare-innovation/) Health innovation     (https://www.swissinfo.ch/eng/topic/prevention/) Prevention    (https://www.swissinfo.ch/eng/topic/ai-and-medicine/) AI and medicine    (https://www.swissinfo.ch/eng/topic/new-treatments/) New treatments       (https://www.swissinfo.ch/eng/agribusiness/) Agribusiness     (https://www.swissinfo.ch/eng/topic/food-supply-chains/) Food supply chains    (https://www.swissinfo.ch/eng/topic/food-safety/) Food safety        (https://www.swissinfo.ch/eng/health-economy) Top stories     (Chocolate and cocao beans)   Traces of cadmium found in most Swiss foodstuffs  (https://www.swissinfo.ch/eng/agribusiness/traces-of-cadmium-found-in-most-swiss-foodstuffs/91964321) Read more: Traces of cadmium found in most Swiss foodstuffs    (lab)   Swiss non-profit drugmakers team up as funding shrinks  (https://www.swissinfo.ch/eng/new-treatments/swiss-non-profit-drugmakers-team-up-as-funding-shrinks/91946832) Read more: Swiss non-profit drugmakers team up as funding shrinks    (Medicine packet)   US price pressure ‘threatens new drugs’ in Switzerland  (https://www.swissinfo.ch/eng/medicine-access/us-price-pressure-threatens-new-drugs-in-switzerland/91943916) Read more: US price pressure ‘threatens new drugs’ in Switzerland    (The average cost of developing a new drug, from discovery to launch, reached $2.23 billion in 2024 for the world's 20 biggest biopharma companies – a 65% jump from 2014.)   Why drugs are becoming more expensive to develop  (https://www.swissinfo.ch/eng/healthcare-innovation/why-drugs-are-becoming-more-expensive-to-develop/91851935) Read more: Why drugs are becoming more expensive to develop    (https://www.swissinfo.ch/eng/health-economy) See all economy stories       (https://www.swissinfo.ch/eng/podcasts/) Podcasts          (lost cell podcast cover art)   Reality hits: hard truths come to light in the final episode of ‘Lost Cells’  (https://www.swissinfo.ch/eng/archive-science/reality-hits-hard-truths-come-to-light-in-the-final-episode-of-lost-cells/89003208) Read more: Reality hits: hard truths come to light in the final episode of ‘Lost Cells’    (https://www.swissinfo.ch/eng/podcasts/) See all podcasts      (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletter     (Newsletter Business)   Business stories by SWI swissinfo.ch  (https://www.swissinfo.ch/eng/archive-banking-fintech/business-stories-by-swi-swissinfo-ch/79227961) Read more: Business stories by SWI swissinfo.ch    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) See all newsletters            (https://www.swissinfo.ch/eng/topic/swiss-abroad-community/) Swiss abroad community      (https://www.swissinfo.ch/eng/topic/swiss-politics/) Swiss politics      (https://www.swissinfo.ch/eng/referendums-and-federal-politics-for-swiss-abroad/) Votes      (https://www.swissinfo.ch/eng/moving-abroad/) Moving abroad      (https://www.swissinfo.ch/eng/swiss-oddities/) Swiss oddities       (https://www.swissinfo.ch/eng/topic/swiss-abroad-community/) Top stories     (Chocolate and cocao beans)   Traces of cadmium found in most Swiss foodstuffs  (https://www.swissinfo.ch/eng/agribusiness/traces-of-cadmium-found-in-most-swiss-foodstuffs/91964321) Read more: Traces of cadmium found in most Swiss foodstuffs    (Let's Talk programme)   ‘Neutrality alone does not protect Switzerland against aggression’  (https://www.swissinfo.ch/eng/votes/neutrality-alone-does-not-protect-switzerland-against-aggression/91956404) Read more: ‘Neutrality alone does not protect Switzerland against aggression’    (Elio Biadici in front of his house in Piano di Peccia, in the Maggia Valley, southern Switzerland on July, 3, 2024. Heavy thunderstorms triggered devastating debris flows and damage in the region in late June 2024.)   Why Alpine debris flows are becoming more intense and unpredictable  (https://www.swissinfo.ch/eng/climate-adaptation/why-alpine-debris-flows-are-becoming-more-intense-and-unpredictable/91643844) Read more: Why Alpine debris flows are becoming more intense and unpredictable    (https://www.swissinfo.ch/eng/topic/swiss-abroad-community/) See all Swiss abroad stories       (https://www.swissinfo.ch/eng/about-us/the-swiplus-app-your-connection-to-switzerland/46766802) Stay in touch with Switzerland     (SWIplus Stay in touch with Switzerland)   The SWIplus app: your connection to Switzerland  (https://www.swissinfo.ch/eng/about-us/the-swiplus-app-your-connection-to-switzerland/46766802) Read more: The SWIplus app: your connection to Switzerland              (https://www.swissinfo.ch/eng/topic/global-health/) Global health      Ebola vaccine: ‘In an outbreak situation we’re racing against time’   (Teams from the International Federation of the Red Cross and Red Crescent Societies prepare for burial at Mbiyo cemetery the body of a fourth orphan who died from Ebola virus disease at an orphanage in Bunia, Ituri Province, June 19, 2026)  Teams from the International Federation of the Red Cross and Red Crescent Societies prepare for burial at Mbiyo cemetery the body of a fourth orphan who died from Ebola virus disease at an orphanage in Bunia, Ituri Province, June 19, 2026  Jospin Mwisha / AFP    Efforts to develop a vaccine against the current Ebola outbreak in the Democratic Republic of Congo (DRC) have already achieved initial successes thanks to an innovative funding strategy.            Listen to the article  Listening the article   Toggle language selector       Select your language  Close                                                            English (US)                         English (British)         Generated with artificial intelligence.    (Ebola vaccine: ‘In an outbreak situation we’re racing against time’)  Listening:  Ebola vaccine: ‘In an outbreak situation we’re racing against time’    Close             Share         This content was published on  August 25, 2026 - 09:00         7 minutes       Annegret Mathari       Annegret Mathari has been reporting on International Geneva for more than two decades. For swissinfo she covers the UN and other Geneva-based international organisations. She writes on international diplomatic negotiations, human rights issues, humanitarian aid, armed conflicts, health and the environment.     (https://www.swissinfo.ch/eng/author/annegret-mathari/) More from this author           Other language: 1  EN original       العربية  ar     لمواجهة إيبولا…العلماء في سباق مع الزمن   (https://www.swissinfo.ch/ara/%d8%a7%d9%84%d8%b5%d8%ad%d8%a9-%d8%a7%d9%84%d8%b9%d8%a7%d9%84%d9%85%d9%8a%d8%a9/%d9%84%d9%82%d8%a7%d8%ad-%d8%a5%d9%8a%d8%a8%d9%88%d9%84%d8%a7-%d9%81%d9%8a-%d8%ae%d8%b6%d9%85-%d8%aa%d9%81%d8%b4%d9%8d%d9%91-%d9%88%d8%a8%d8%a7%d8%a6%d9%8a-%d9%86%d8%ad%d9%86-%d9%81%d9%8a-%d8%b3%d8%a8%d8%a7%d9%82-%d9%85%d8%b9-%d8%a7%d9%84%d8%b2%d9%85%d9%86/91945934) Read more: لمواجهة إيبولا…العلماء في سباق مع الزمن          With no approved vaccine or treatment available for the Bundibugyo strain of Ebola, the outbreak in the Democratic Republic of Congo (DRC) has triggered an urgent scientific response. Researchers have compressed years of vaccine development into weeks, launching the first human trials as the Geneva-based World Health Organization (WHO) warns that the epidemic could reach unprecedented proportions. “The search for a Bundibugyo Ebola vaccine is a race against time,” said Rachael Bonawitz, head of the Filovirus Disease Programme at the Coalition for Epidemic Preparedness Innovations (CEPI).  With thousands of infections already reported and the virus spreading rapidly across eastern Congo, scientists, global health organisations and vaccine manufacturers are moving at exceptional speed to develop, test and produce vaccine candidates before the outbreak expands further. The Bundibugyo strain, responsible for the current epidemic, is both highly contagious and highly lethal. Unlike the Zaire strain of Ebola, for which licensed vaccines and treatments exist, there are currently no approved medical countermeasures against Bundibugyo. According to Tedros Adhanom Ghebreyesus, director of the WHO, 4,449 cases had been reported in the DRC by August 12. A total of 2,061 people had died, while 886 patients recovered despite the absence of specific therapies and vaccines, several of which are now undergoing testing. The highly infectious Ebola virus is transmitted through bodily fluids and can cause severe fever, internal and external bleeding, and organ failure. For health officials, containing the outbreak is not simply a national challenge but a regional priority. The longer transmission continues, the greater the risk of cases spreading across borders. (A hygiene worker disinfects a person's feet at the entrance to the Rwampara Ebola Treatment Centre (ETC) in Bunia, Ituri, in the east of the Democratic Republic of Congo on July 13, 2026.)  A hygiene worker disinfects a person’s feet at the entrance to the Rwampara Ebola Treatment Centre (ETC) in Bunia, Ituri, in the east of the Democratic Republic of Congo on July 13, 2026.  Benediction Murhabazi / AFP    Vaccine challenges Yet developing vaccines against emerging epidemic threats presents a fundamental challenge. Outbreaks are rare, unpredictable and often short-lived, leaving pharmaceutical companies with little commercial incentive to invest. “Because outbreaks are rare and sporadic, vaccine developers do not have a reliable market,” Bonawitz told Swissinfo. “Given uncertain demand, a lack of guaranteed buyers and limited financial returns, this can create significant costs for developers.” Without intervention, she warned, the world risks finding itself without a vaccine every time a new outbreak emerges. To address this market failure, CEPI, a non-profit organisation based in Oslo, and Gavi, the Vaccine Alliance, based in Geneva, launched an innovative financing strategy in June that combines so-called push and pull mechanisms. CEPI provides the push funding, financing vaccine research and development. The organisation has committed more than $60 million to advance a portfolio of Bundibugyo vaccine candidates. CEPI is supported by private investors, philanthropy and states – Switzerland has committed $22.7 million (CHF18.2 million) between 2022 and 2026. More ()   More  International Geneva   Inside Geneva Summer profile: tackling Ebola in DRC  This content was published on  Jul 21, 2026   Trish Newport, a nurse with MSF, always knew she would work for the NGO. Today she’s in DRC tackling the current Ebola outbreak.    (https://www.swissinfo.ch/eng/international-geneva/inside-geneva-summer-profile-tackling-ebola-in-drc/91777904) Read more: Inside Geneva Summer profile: tackling Ebola in DRC    “This early-stage funding is critical to reducing the scientific and technical risks for developers and moving a vaccine candidate from the laboratory into clinical trials,” Bonawitz explained. Rather than backing a single vaccine, CEPI is supporting several candidates simultaneously. The portfolio approach increases the likelihood that at least one vaccine will prove safe and effective and can be deployed rapidly if the outbreak worsens. Gavi’s contribution focuses on the commercial risks that often slow vaccine development even after promising results emerge. Through its First Response Fund, the alliance has approved up to $40 million to help manufacturers invest in production capacity before it is known whether a vaccine will ultimately succeed. This is intended to ensure that vaccine doses can be made available quickly once clinical trials produce encouraging results. “This emergency financing is about securing speed, capacity and access,” Emanuele Capobianco, Gavi’s Director of Global Health Security, said in a statement. First clinical trials The strategy is already producing results. The first vaccine candidate specifically targeting the Bundibugyo strain entered Phase 1 clinical testing in the United Kingdom on July 24. Developed by the University of Oxford and the Serum Institute of India (SII), the candidate, known as ChAdOx1 BDBV, is based on the same viral-vector technology used in the Oxford-AstraZeneca Covid-19 vaccine. Oxford researchers developed the vaccine in just eight weeks, significantly faster than was possible during the Covid-19 pandemic. The first volunteer to receive the experimental vaccine was 37-year-old Briton Ed Hunt, who said he decided to participate after seeing reports about the deadly outbreak in the DRC. The trial will enrol 50 healthy volunteers aged 18-55 and is designed to assess the vaccine’s safety, tolerability and ability to generate an immune response. (Health Officials Scale Up Operations To Contain Deadly Ebola Outbreak In Congo)  Health officials scale up operations to contain deadly Ebola outbreak in Congo.  Michel Lunanga / Getty Images    A second vaccine candidate, Moderna’s mRNA-1469, entered Phase 1 testing in Canada on August 4. The vaccine uses the same mRNA platform that first gained prominence during the Covid-19 pandemic. Approximately 80 healthy volunteers are expected to participate in the study. Moderna announced that Susan Murray became the first participant to receive the vaccine candidate as part of the CEPI-funded trial. Researchers hope to move rapidly from these early studies to larger Phase 2 and 3 trials if initial results are encouraging. Trial participants will be monitored for up to a year, but scientists expect to obtain preliminary information on immune responses and potential side effects much sooner. At the same time, vaccine manufacturers are already producing doses before any candidate has been proven effective. The Serum Institute of India, the world’s largest vaccine manufacturer, has produced and stockpiled around 620,000 doses of the Oxford vaccine candidate within just two weeks. Around 4,000 doses have been allocated for use in the Phase 1 study. CEPI financed the production of these doses in advance and at financial risk, ensuring supplies would be available immediately for larger trials or emergency deployment if the vaccine proves successful. “If we manufacture doses ahead of time, no time is lost once we determine that a vaccine candidate can move to the next stage of testing and we can start immediately,” Bonawitz said. Referring to the stockpile already prepared by the Serum Institute of India, she added: “In an outbreak situation we’re racing against time.” Meanwhile, the WHO is also exploring whether existing tools could help. In August it recommended that Ervebo, the only licensed Ebola vaccine currently available and originally developed against the Zaire strain, be included in a Phase 3 study against the current strain. The recommendation followed two animal studies that suggested the vaccine may offer some protection against the variant responsible for the current outbreak. Edited by Virginie Mangin/(https://www.swissinfo.ch/eng/author/thomas-stephens/) ts    This article has been corrected on August 25, 2026, to clarify the role of CEPI.      Popular Stories                Most Discussed                              Articles in this story  (https://www.swissinfo.ch/eng/international-geneva/inside-geneva-summer-profile-tackling-ebola-in-drc/91777904) Inside Geneva Summer profile: tackling Ebola in DRC      (JTI Certified) In compliance with the JTI standards   More: (https://www.swissinfo.ch/eng/swi-swissinfo-ch-certified-by-the-journalism-trust-initiative/47111480) SWI swissinfo.ch certified by the Journalism Trust Initiative    You can find an overview of ongoing (https://www.swissinfo.ch/eng/debates/) debates with our journalists here . Please join us!  If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at (mailto:english@swissinfo.ch?subject=Ebola%20vaccine%3A%C2%A0%E2%80%98In%20an%20outbreak%20situation%20we%E2%80%99re%20racing%20against%20time%E2%80%99%C2%A0&body=https%3A%2F%2Fwww.swissinfo.ch%2Feng%2Fglobal-health%2Febola-vaccine-in-an-outbreak-situation-were-racing-against-time%2F91934531) english@swissinfo.ch .    Read more                                                                                                                          Back to top         Follow us  (https://www.facebook.com/swissinfo)      (https://x.com/swissinfo_en)      (https://www.youtube.com/c/swissinfo)      (https://www.instagram.com/swissinfo.ch_en/)      (https://www.tiktok.com/@swissinfo.ch)         Stay informed daily about news in Switzerland with our Briefing in the SWI plus app for the Swiss abroad.  (https://apps.apple.com/ch/app/swi-plus/id1451174842?l=en) (Apple Appstore)    (https://play.google.com/store/apps/details?id=ch.swissinfo.android&hl=en_CH) (Google Play)        (https://www.swissinfo.ch/eng/about-us/imprint/37650898) Imprint    (https://www.swissinfo.ch/eng/about-us/data-privacy-statement/133174) Data Privacy Statement    (https://www.swissinfo.ch/eng/about-us/terms-of-use/44141966) Terms of Use    (https://www.swissinfo.ch/eng/about-us/rights-to-content-and-liability/48761632) Rights to content and liability    Privacy settings        (https://jobs.swissinfo.ch/en/jobs-careers/) Jobs    (https://play.swissinfo.ch/play/tv) Play SWI    (https://www.swissinfo.ch/eng/about-swi/) About us    (https://www.swissinfo.ch/eng/inside-swi/swissinfo-annual-report-2025/91480983) Annual Report 2025    (https://www.swissinfo.ch/eng/about-us/swissinfo-ch-newsletter_newsletter-subscription/42152624) Newsletters    (https://www.swissinfo.ch/eng/podcasts/) Podcasts    (https://www.swissinfo.ch/eng/contact-us-swi/) Contact        SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR  (https://www.srgssr.ch/en/home/) (SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR)    (https://www.rts.ch/) RTS    (https://www.srf.ch/) SRF    (https://www.rsi.ch/) RSI    (https://www.rtr.ch/) RTR             SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR  (https://www.srgssr.ch/en/home/) (SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR)          Sign in and personalize Swissinfo     Follow Topics  Stay up to date with your preferred topics.        Bookmarks  Save articles for later      Sign in   Later   Close         Personal feed  Close       Select topics that interest you.    Save   Cancel